PMID- 15581967
OWN - NLM
STAT- MEDLINE
DCOM- 20050125
LR  - 20141120
IS  - 0090-8258 (Print)
IS  - 0090-8258 (Linking)
VI  - 95
IP  - 3
DP  - 2004 Dec
TI  - ERBB-2 gene overexpression and amplification in uterine sarcomas.
PG  - 583-7
AB  - BACKGROUND: The aim of this study was to determine ERBB-2 (HER-2/neu) gene 
      alterations in different subtypes of uterine sarcomas. METHODS: After central 
      review, representative biopsies were immunohistochemically stained and 
      semiquantitatively scored as negative, weakly (1+), moderately (2+), or strongly 
      (3+) positive. Subsequently, fluorescence in situ hybridization (FISH) was 
      performed on cases with 2+ and 3+ expression. RESULTS: Seventy tumors (52 
      primaries and 18 recurrent) were evaluated. All 10 adenosarcomas, 21 endometrial 
      stromal sarcomas, and 10 leiomyosarcomas were negative both in the primary and 
      recurrent setting. Twenty-two primary carcinosarcomas were scored. The epithelial 
      component was negative/1+ in 16 (73%), 2+/3+ in five (22.5%) tumors, and could 
      not be evaluated in one case (4.5%), whereas the sarcoma component stained 
      negative/1+ in 21 cases (95.5%) and 3+ (4.5%) in one case. In two recurrent 
      carcinosarcomas, the epithelial component stained 3+ in both cases, whereas the 
      sarcoma component scored negative and 1+. Amplification of the ERBB-2 gene as 
      determined by FISH was observed in 3/7 (43%) carcinosarcomas with 2+ or 3+ 
      overexpression, resulting in an overall 3/22 (14%) amplification rate. One out of 
      four undifferentiated uterine sarcomas stained 2+. ERBB-2 immunopositivity (3+) 
      and ERBB-2 amplification by FISH were confirmed in the recurrent tumor, resulting 
      in a gene amplification rate of 1/4 in undifferentiated uterine sarcomas. 
      CONCLUSION: The current results suggest absence of ERBB-2 overexpression in 
      uterine leiomyosarcoma, uterine adenosarcoma, and endometrial stromal sarcoma, 
      whereas the ERBB-2 gene might have a biologic role in uterine carcinosarcoma and 
      undifferentiated uterine sarcomas.
FAU - Amant, Frederic
AU  - Amant F
AD  - Division of Gynecologic Oncology, University Hospitals Leuven, Herestraat 49, 
      3000 Leuven, Belgium. Frederic.amant@uz.kuleuven.ac.be
FAU - Vloeberghs, Veerle
AU  - Vloeberghs V
FAU - Woestenborghs, Heidi
AU  - Woestenborghs H
FAU - Debiec-Rychter, Maria
AU  - Debiec-Rychter M
FAU - Verbist, Lieve
AU  - Verbist L
FAU - Moerman, Philippe
AU  - Moerman P
FAU - Vergote, Ignace
AU  - Vergote I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenosarcoma/genetics/metabolism
MH  - Carcinosarcoma/genetics/metabolism
MH  - Female
MH  - Gene Amplification
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Interphase/genetics
MH  - Leiomyosarcoma/genetics/metabolism
MH  - Receptor, ErbB-2/biosynthesis/genetics
MH  - Sarcoma/*genetics/metabolism
MH  - Sarcoma, Endometrial Stromal/genetics/metabolism
MH  - Uterine Neoplasms/*genetics/metabolism
EDAT- 2004/12/08 09:00
MHDA- 2005/01/26 09:00
CRDT- 2004/12/08 09:00
PHST- 2004/04/24 00:00 [received]
PHST- 2004/12/08 09:00 [pubmed]
PHST- 2005/01/26 09:00 [medline]
PHST- 2004/12/08 09:00 [entrez]
AID - S0090-8258(04)00561-X [pii]
AID - 10.1016/j.ygyno.2004.07.041 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2004 Dec;95(3):583-7. doi: 10.1016/j.ygyno.2004.07.041.